表紙
市場調査レポート

RORγ調節因子:RORγ拮抗薬と作動薬の状況の比較分析

RORgamma Modulators 2016: A Comparative Analysis of the Landscape of RORgamma Antagonists and Agonists

発行 La Merie Publishing 商品コード 351304
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
RORγ調節因子:RORγ拮抗薬と作動薬の状況の比較分析 RORgamma Modulators 2016: A Comparative Analysis of the Landscape of RORgamma Antagonists and Agonists
出版日: 2016年02月03日 ページ情報: 英文 88 Pages
概要

レチノイン酸関連オーファン核内受容体γ (RORγ) は、注目を集めつつも「難しい」薬剤標的です。現在、30社以上が、創薬と開発に力を注いでいます。

当レポートでは、炎症性・自己免疫疾患に対するRORγ拮抗薬とがん治療に対するRORγ作動薬について取り上げ、それぞれの科学的論拠について検証して、体系的な情報を提供しています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 標的の背景

第4章 標的の検証

  • Anti-IL17抗体の臨床的成功
  • 非臨床的な標的の検証
  • RORγ拮抗薬に対する臨床的な主適応
  • 標的関連の潜在的な安全上の懸念

第5章 創薬アプローチと技術

  • 創薬の共同研究
  • RORγ調節因子の創薬共同研究の商業的価値
  • パートナーシッププログラムにおけるRORγ拮抗薬の創薬R&Dタイムライン
  • 核内受容体リガンドの創薬戦略

第6章 RORγ調節因子の競合情勢

  • 炎症性・自己免疫疾患に対するRORγ拮抗薬
  • がんに対するRORγ作動薬

第7章 企業ステークホルダー

  • 非パートナー技術企業
  • パートナーシップ
  • 非パートナー製薬企業

第8章 参考資料

図表

目次
Product Code: LMFR0017

Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but "difficult-to-drug" target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and more to follow in 2016 and thereafter.

The report explains the scientific rationale for discovering antagonists of RORgamma for treatment of autoimmune and inflammatory diseases, but also of agonists of RORgamma for treatment of cancer. Clinical as well as non-clinical data for target validation of RORgamma are provided. Lead and up-side indications for development including the key product profile are discussed. Potential safety concers for novel RORgamma modulators were identified. Drug discovery approaches of technology and pharmaceutical companies are shown regarding strategies in partnering as well as in technologies applied for structure-based drug discovery. Based on the experience in the past, estimates of the required time from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects is analyzed and the profiles of companies elaborated, separately for unpartnered technology or pharmaceutical companies and for partnerships between technology and pharmaceutical companies.

The report provides an understanding of:

  • The target RORgamma
  • Clinical and non-clinical target validation
  • Clinical lead and up-side indications
  • Drug discovery strategies and technologies
  • Commercial value of drug discovery collaborations
  • R&D timelines from start of screening to first-in-human studies
  • Competitive landscape of RORgamma antagonists
  • Agonists of RORgamma for cancer
  • Profiles of unpartnered technology companies and lead projects
  • R&D Partnerships and their discovery approaches and lead molecules
  • Unpartnered pharmaceutical companies and their programs

Table of Contents

1) Introduction

2) Executive Summary

3) Target Background

4) Target validation

  • Clinical Success of Anti-IL17 Antibodies
  • Non-Clinical Target Validation
  • Clinical Lead Indication for RORgamma Antagonists
  • Target-related Potential Safety Concerns

5) Drug Discover Approaches & Technologies

  • Drug Discovery Collaboration
  • Commercial Value of RORgamma Modulator Drug Discovery Collaborations
  • R&D Timelines for Discovery of RORgamma Antagonists in Partnership Programs
  • Strategies for the Discovery of Nuclear Receptor Ligands

6) Competitive Landscape of RORgamma Modulators

  • RORgamma Antagonists for Inflammatory and Autoimmune Diseases
  • Agonists of RORgamma for Cancer

7) Corporate Stakeholders

  • Unpartnered Technology Companies
  • Partnerships
  • Unpartnered Pharmaceutical Companies

8) References

Tables in the report

  • Table 1: Disease Models Used for Non-Clinical Studies of RORgamma Antagonists
  • Table 2: Overview of Non-Clinical Studies of RORgamma Antagonists in Psoriasis Models
  • Table 3: Overview of Non-Clinical Studies of RORgamma Antagonists in Multiple Sclerosis Models
  • Table 4: Overview of Non-Clinical Studies of RORgamma Antagonists in Arthritis Models
  • Table 5: Overview of Non-Clinical Studies of RORgamma Antagonists in Inflammatory Bowel Disease and Ulcerative Colitis Models
  • Table 6: Overview of Non-Clinical Studies of RORgamma Antagonists in Systemic Lupus Erythematosus Models
  • Table 6: Overview of Partnership Agreements for RORgamma Modulators
  • Table 7: Special Collaborations for Discovery of RORgamma Antagonists
  • Table 8: Financial Terms of Partnership Agreements for RORgamma Modulators
  • Table 9: R&D Timeline for Discovery of RORgamma Antagonists in Partnership Programs
  • Table 10: Technologies for Discovery of RORgamma Antagonists
  • Table 11: RORgamma(T) Antagonists / Inverse Agonists in Clinical Development
  • Table 12: RORgamma(T) Antagonists / Inverse Agonists in pre-IND Studies
  • Table 13: RORgamma(T) Antagonists / Inverse Agonists in Preclinical R&D
  • Table 14: RORgamma(T) Antagonists / Inverse Agonists Discovery Programs
  • Table 15: RORgamma Agonists Discovery & Development Programs
  • Table 16: Technology and Pharma Companies with RORgamma Modulator R&D

Companies mentioned in the report

  • 4SC Discovery
  • Advinus Therapeutics
  • Amgen
  • Argenta
  • Arrien Pharmaceuticals
  • AstraZeneca
  • Aurigene Discovery Technologies
  • Biogen
  • Boehringer Ingelheim
  • Brickell Biotech
  • Bristol-Myers Squibb
  • Celgene
  • Daiichi Sankyo
  • Exelixis
  • Genfit
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Innovimmune Biotherapeutics
  • Janssen Biotech
  • Japan Tobacco
  • Karo Bio
  • Lycera
  • Merck
  • Nuevolution
  • ORCA Pharmaceuticals
  • Orphagen Pharmaceuticals
  • Pfizer
  • Phenex Pharmaceuticals
  • Piramal (& Krish Biotech)
  • Roche
  • Takeda Pharmaceutical Co.
  • Teijin Pharma
  • Tempero Pharmaceuticals
  • Visionary Pharmaceuticals
  • Vitae Pharmaceuticals
Back to Top